Clearmind Medicine (SPRC): Price to Sales

Symbol and logo of brand Clearmind Medicine (SPRC)

The absence of recurring revenue makes the financial position of SciSparc Ltd (SPRC) dependent on test outcomes. The price-to-sales multiple reflects market valuation trends, with the indicator currently standing at 1.10. SciSparc Ltd focuses on cannabinoid-based therapies for Alzheimer's and Tourette syndrome, expanding its total addressable market. Intensive R&D efforts and anticipated mid-stage molecule trial data confirm a high pace of innovation.

SciSparc (SPRC): P/S Multiple from 02/21/2024 to 11/13/2026

Metric breakdowns and analytics for Clearmind Medicine (SPRC)

- share price and consensus valuation forecast:
Price Performance Chart scisparc.com|SPRC - Price Target Chart
- stock exchange capitalization data:
Market Value Clearmind Medicine|SPRC - Total Company Value
- shareholders' equity book value data:
Net Assets per Share SciSparc|SPRC - Book Capitalization|Market Cap to Net Assets Ratio scisparc.com|SPRC - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient SciSparc Ltd|SPRC - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient SciSparc Corp|SPRC - Company Debts|Debts to Book Capitalization Ratio Clearmind Medicine|SPRC - Company Long-Term Debts|Company Short-Term Debts SciSparc|Intermediate Coverage Ratio scisparc.com
- net income and valuation ratios data:
SPRC - Net Profit|Future Profit SciSparc Ltd|SPRC - Price to Earnings Ratio|Future Price to Earnings Multiple SciSparc Ltd.|SPRC - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clearmind Medicine|SPRC - Operating profit before deduction of amortization|Earnings per share for the last four quarters SciSparc|SPRC - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months scisparc.com|SPRC - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year SciSparc Ltd
- issuer revenue and sales details:
SPRC - Company Revenue|Company Expected Revenue scisparc.com|SPRC - Price-to-Revenue Ratio|Forward Price to Sales Clearmind Medicine
Fundamental company analysis:scisparc.com - SPRC
Core merchandise of SciSparc Ltd

To assess an asset's operational resilience, an investor analyzes the ratio of market capitalization to annual revenue, which determines the cost of each dollar of sales. By tracking the price/sales multiple on the GURU.Markets platform, one can evaluate the fundamental value of SciSparc Ltd (SPRC), given that patent protection and the high cost of neurobiological research create significant barriers to entry for competitors, ensuring the long-term viability of the business.

Competing companies

ALKS (alkermes.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Avadel Pharmaceuticals plc AVDL|atai Life Sciences NV (ATAI) - Price to Sales|GHRS - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Mind Medicine Corp MNMD|CMPS: P/S Multiple|Market Cap to Revenue lbpharma.us|DRUG (Bright Minds Biosciences Inc.) - P/S Multiple|Vanda Pharma (VNDA) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Cybin Inc. (CYBN)|Price-to-Revenue Coefficient Alto Neuroscience Corp|Price-to-Revenue Ratio NRx Pharmaceuticals NRXP|CING (Cingulate Inc) - Price-to-Sales Ratio|Silo Pharma, Inc. - P/S Multiple|CPHI - P/S Multiple|Clearmind Medicine (CMND) - Price-to-Revenue Ratio|Psyence Bio - Market Capitalization-to-Revenue Ratio|SEEL (Seelos Therapeutics) - P/S Multiple|Market Cap to Revenue Virpax (VRPX)|Market Cap to Revenue KRTX (Karuna Therapeutics, Inc.)